89060-38-8Relevant academic research and scientific papers
1, 3-diaryl-1, 2, 4-triazole compound as well as preparation method and application thereof
-
, (2021/01/29)
The invention discloses a 1, 3-diaryl-1, 2, 4-triazole compound, which has a novel structure shown in a structural general formula I and has better selective inhibition activity on HDAC6. The invention also discloses a preparation method of the compound, aryl groups and 4-amino-N-hydroxy-benzamide groups are introduced to a 1, 2, 4-triazole matrix for modification, a series of compounds with novelstructures are synthesized, and the method has the advantages of mild reaction conditions, simple operation, high yield and the like. The invention also discloses an application of the compound in preparation of a medicine for selectively inhibiting HDAC6. The compound provided by the invention can significantly inhibit HDAC6, the IC50 value of the compound is at a nanomole level, the dosage of apatient is favorably reduced, and the toxic and side effects of the medicine on a human body are reduced. The compound provided by the invention has high selectivity on subtype HDAC1, can effectivelyavoid toxic and side effects of a drug on normal tissues of a human body, and shows good development potential.
Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity
Zhang, Xin-Hui,Kang, Hui-Qin,Tao, Yuan-Yuan,Li, Yi-Han,Zhao, Jun-Ru,Ya-Gao,Ma, Li-Ying,Liu, Hong-Min
, (2021/04/12)
Histone deacetylase 6 (HDAC6) has emerged as a critical regulator of many cellular pathways in tumors due to its unique structure basis and abundant substrate types. Over the past few decades, the role played by HDAC6 inhibitors as anticancer agents has sparked great interest of biochemists worldwide. However, they were less reported for gastric cancer therapy. In this paper, with the help of bioisosteric replacement, in-house library screening, and lead optimization strategies, we designed, synthesized and verified a series of 1,3-diaryl-1,2,4-triazole-capped HDAC6 inhibitors with promising anti-gastric cancer activities. Amongst, compound 9r displayed the best inhibitory activity towards HDAC6 (IC50 = 30.6 nM), with 128-fold selectivity over HDAC1. Further BLI and CETSA assay proved the high affinity of 9r to HDAC6. In addition, 9r could dose-dependently upregulate the levels of acetylated α-tubulin, without significant effect on acetylated histone H3 in MGC803 cells. Besides, 9r exhibited potent antiproliferative effect on MGC803 cells, and promoted apoptosis and suppressed the metastasis without obvious toxicity, suggesting 9r would serve as a potential lead compound for the development of novel therapeutic agents of gastric cancer.
3-Phenyl-1,2,4-triazole-5-carbaldehydes Substituted in Position 1
Moderhack, Dietrich
, p. 48 - 65 (2007/10/02)
The aldehydes 7 - first examples of the yet unknown class of 1,2,4-triazole-5-carbaldehydes substituted in position 1 - can be obtained in excellent yield by lead tetraacetate oxidation of 2; the Kroehnke reaction with 5 provides an alternative route.Due
1-AZADIENES AS A SYNTHON FOR HETEROCYCLIC SYNTHESIS
Ohshiro, Yoshiki,Komatsu, Mitsuo,Uesaka, Masatoshi,Agawa, Toshio
, p. 549 - 559 (2007/10/02)
1-Azabutadienes 1 were found to be a good building block for three- to five-membered heterocycles having a functional group.Oxidation of 1 with mCPBA afforded 3-alkenyloxaziridines 2.Cycloaddition of 1 with ketenes gave the 4-alkenylazetidinones 6.Addition of a nitrile imine occured across the C=N bond to give the 3-alkenyltriazoline 8, while that of a nitrile ylide occurred on the C=C bond to give the 3-formylpyrrole 14 formed by hydrolysis of the C=N bond.
